Finerenone, a novel selective non-steroidal mineralocorticoid receptor antagonist with a balanced cardiorenal tissue distribution confers pronounced end organ protection at low natriuretic doses

被引：0
|
作者：
Kolkhof, P. [1 ]
Delbeck, M. [1 ]
Kretschmer, A. [2 ]
Steinke, W. [3 ]
Hartmann, E. [4 ]
Baerfacker, L.
Eitner, F. [1 ]
Albrecht-Kuepper, B. [1 ]
Schaefer, S. [2 ]
机构：
[1] BAYER HealthCare, Global Drug Discovery, Cardiol Res, Wuppertal, Germany
[2] BAYER HealthCare, Global Drug Discovery, Clin Sci, Wuppertal, Germany
[3] BAYER HealthCare, Inst Toxicol, Wuppertal, Germany
[4] BAYER HealthCare, Global Drug Discovery, Lead Discovery, Wuppertal, Germany
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2014年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：210 / 210
页数：1
相关论文
共 14 条
  • [1] Non-steroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection is a New Option for Patients with Chronic Kidney Disease
    Liu, Wenyu
    Yu, Shengqiang
    KIDNEY DISEASES, 2023, 9 (01) : 12 - 25
  • [2] Effects Of Finerenone - A Novel Non-steroidal Mineralocorticoid Receptor Antagonist In A Model Of Pressure Overload-induced Cardiac Hypertrophy
    Grune, Jana
    Benz, Verena
    Brix, Sarah
    Ban, Zsofia
    Salatzki, Janek
    Hoeft, Beata
    Foryst-Ludwig, Anna
    Klopfleisch, Robert
    Kolkhof, Peter
    Kintscher, Ulrich
    HYPERTENSION, 2014, 64
  • [3] Effects of Finerenone - a novel non-steroidal mineralocorticoid receptor antagonist in a model of pressure overload-induced cardiac hypertrophy
    Grune, J.
    Benz, V
    Brix, S.
    Ban, Z.
    Janek, S.
    Foryst-Ludwig, A.
    Klopfleisch, R.
    Kolkhof, P.
    Kintscher, U.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2015, 388 : S35 - S35
  • [4] Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys
    Yamada, Makiko
    Takei, Makoto
    Suzuki, Eiko
    Takakusa, Hideo
    Kotsuma, Masakatsu
    Washio, Takuo
    Murayama, Nobuyuki
    Inoue, Shin-ichi
    Izumi, Takashi
    XENOBIOTICA, 2017, 47 (12) : 1090 - 1103
  • [5] Cardiorenal protection by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist in a preclinical model of hypertension and diastolic heart failure
    Delbeck, M.
    Kretschmer, A.
    Kast, R.
    Baerfacker, L.
    Hartmann, E.
    Schaefer, S.
    Kolkhof, P.
    EUROPEAN HEART JOURNAL, 2012, 33 : 772 - 773
  • [6] Pronounced cardiac protection by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist in a preclinical rat model of heart failure
    Albrecht-Kuepper, B.
    Kretschmer, A.
    Kast, R.
    Baerfacker, L.
    Schaefer, S.
    Kolkhof, P.
    EUROPEAN HEART JOURNAL, 2012, 33 : 7 - 7
  • [7] The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease
    Barrera-Chimal, Jonatan
    Gerarduzzi, Casimiro
    Rossignol, Patrick
    Jaisser, Frederic
    CLINICAL SCIENCE, 2022, 136 (12) : 1005 - 1017
  • [8] The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure A systematic review and meta-analysis
    Pei, Hui
    Wang, Wei
    Zhao, Di
    Wang, Lei
    Su, Guo-Hai
    Zhao, Zhuo
    MEDICINE, 2018, 97 (16)
  • [9] Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist
    Arai, Kiyoshi
    Homma, Tsuyoshi
    Morikawa, Yuka
    Ubukata, Naoko
    Tsuruoka, Hiyoyuki
    Aoki, Kazumasa
    Ishikawa, Hirokazu
    Mizuno, Makoto
    Sada, Toshio
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2015, 761 : 226 - 234
  • [10] Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug–Drug Interaction Studies In Vitro and In Vivo
    Roland Heinig
    Michael Gerisch
    Anna Engelen
    Johannes Nagelschmitz
    Stephanie Loewen
    European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43 : 715 - 727
12